Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma - Institut Gustave Roussy Accéder directement au contenu
Article Dans Une Revue Journal of Clinical Oncology Année : 2023

Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma

Pierre Thirion
  • Fonction : Auteur
Matthew Nankivell
Kathryn Winter
  • Fonction : Auteur
Hong Yang
Thomas Walsh
  • Fonction : Auteur
Jurjen Boonstra
David Cunningham
Joel Tepper
Val Gebski
Xavier Paoletti
Jianhua Fu
Jean-Pierre Pignon

Résumé

PURPOSE The optimal neoadjuvant treatment for resectable carcinoma of the thoracic esophagus (TE) or gastroesophageal junction (GEJ) remains a matter of debate. We performed an individual participant data (IPD) network meta-analysis (NMA) of randomized controlled trials (RCTs) to study the effect of chemotherapy or chemoradiotherapy, with a focus on tumor location and histology subgroups. PATIENTS AND METHODS All, published or unpublished, RCTs closed to accrual before December 31, 2015 and having compared at least two of the following strategies were eligible: upfront surgery (S), chemotherapy followed by surgery (CS), and chemoradiotherapy followed by surgery (CRS). All analyses were conducted on IPD obtained from investigators. The primary end point was overall survival (OS). The IPD-NMA was analyzed by a one-step mixed-effect Cox model adjusted for age, sex, tumor location, and histology. The NMA was registered in PROSPERO (CRD42018107158). RESULTS IPD were obtained for 26 of 35 RCTs (4,985 of 5,807 patients) corresponding to 12 comparisons for CS-S, 12 for CRS-S, and four for CRS-CS. CS and CRS led to increased OS when compared with S with hazard ratio (HR) = 0.86 (0.75 to 0.99), P = .03 and HR = 0.77 (0.68 to 0.87), P < .001 respectively. The NMA comparison of CRS versus CS for OS gave a HR of 0.90 (0.74 to 1.09), P = .27 (consistency P = .26, heterogeneity P = .0038). For CS versus S, a larger effect on OS was observed for GEJ versus TE tumors ( P = .036). For the CRS versus S and CRS versus CS, a larger effect on OS was observed for women ( P = .003, .012, respectively). CONCLUSION Neoadjuvant chemotherapy and chemoradiotherapy were consistently better than S alone across histology, but with some variation in the magnitude of treatment effect by sex for CRS and tumor location for CS. A strong OS difference between CS and CRS was not identified.
Fichier principal
Vignette du fichier
Individual_Participant_Data_Network_Meta-Analysis_of_Neoadjuvant_Chemotherapy_or_Chemoradiotherapy_in_Esophageal_or_Gastroesophageal_Junction_Carcinoma.pdf (1.45 Mo) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-04250829 , version 1 (04-04-2024)

Identifiants

Citer

Matthieu Faron, Maurice Cheugoua-Zanetsie, Jayne Tierney, Pierre Thirion, Matthew Nankivell, et al.. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma. Journal of Clinical Oncology, 2023, 41 (28), pp.4535-4547. ⟨10.1200/JCO.22.02279⟩. ⟨hal-04250829⟩
27 Consultations
1 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More